高热膀胱内化疗与其他灌注方法治疗中、高危非肌浸润性膀胱癌的有效性和安全性比较:系统回顾与元分析

IF 2.2 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL International Journal of Clinical Practice Pub Date : 2024-05-09 DOI:10.1155/2024/9916707
Yingying Yang, Hongquan Liu, Yongli Chu, Jipeng Wang, Jian Ma, Guixin Ding, Xingjun Bao, Yuanshan Cui, Jitao Wu
{"title":"高热膀胱内化疗与其他灌注方法治疗中、高危非肌浸润性膀胱癌的有效性和安全性比较:系统回顾与元分析","authors":"Yingying Yang,&nbsp;Hongquan Liu,&nbsp;Yongli Chu,&nbsp;Jipeng Wang,&nbsp;Jian Ma,&nbsp;Guixin Ding,&nbsp;Xingjun Bao,&nbsp;Yuanshan Cui,&nbsp;Jitao Wu","doi":"10.1155/2024/9916707","DOIUrl":null,"url":null,"abstract":"<p><i>Background</i>. In order to prevent the recurrence and progression of intermediate- and high-risk non-muscle invasive bladder cancer (NMIBC) after transurethral resection of bladder tumor (TURBT), various bladder instillation therapies have been developed in recent years. Among these, device-assisted Hyperthermic Intravesical Chemotherapy (HIVEC) has received a great deal of attention. <i>Objective</i>. To identify the efficacy and safety of HIVEC, we conducted this meta-analysis. <i>Methods</i>. We identified relevant articles from PubMed, Embase, and Cochrane Library databases. All published randomized controlled trials (RCTs) describing the role of bladder instillation for the treatment of intermediate- and high-risk NMIBC were involved. Outcomes included 1–3 years Recurrence-Free Survival (RFS), 1–3 years Progression-Free Survival (PFS), 5 years Overall Survival (OS), Adverse Events (AEs), and relevant subgroup analyses. <i>Result</i>. Our study involved a total of 10 RCTs and 1360 patients. In subgroup analysis, we found that compared to MMC instillation, HIVEC decreased the 1–3 years RFS (OR = 0.51; <i>p</i> = 0.009) while not increasing the incidence of AEs (OR = 0.86; <i>p</i> = 0.30). Compared with BCG instillation, HIVEC reduced the incidence of serious AEs (OR = 0.21; <i>p</i> = 0.04) while bringing the same efficacy (OR = 0.78; <i>p</i> = 0.63). <i>Conclusion</i>. HIVEC combined the advantages of efficacy and safety compared with the two recommended instillation modalities. As a potential alternative therapy, its widespread clinical effect remains to be further evaluated.</p>","PeriodicalId":13782,"journal":{"name":"International Journal of Clinical Practice","volume":"2024 1","pages":""},"PeriodicalIF":2.2000,"publicationDate":"2024-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The Efficacy and Safety of Hyperthermic Intravesical Chemotherapy Compared with Other Instillation Methods in Treating Intermediate- and High-Risk Non-Muscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis\",\"authors\":\"Yingying Yang,&nbsp;Hongquan Liu,&nbsp;Yongli Chu,&nbsp;Jipeng Wang,&nbsp;Jian Ma,&nbsp;Guixin Ding,&nbsp;Xingjun Bao,&nbsp;Yuanshan Cui,&nbsp;Jitao Wu\",\"doi\":\"10.1155/2024/9916707\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><i>Background</i>. In order to prevent the recurrence and progression of intermediate- and high-risk non-muscle invasive bladder cancer (NMIBC) after transurethral resection of bladder tumor (TURBT), various bladder instillation therapies have been developed in recent years. Among these, device-assisted Hyperthermic Intravesical Chemotherapy (HIVEC) has received a great deal of attention. <i>Objective</i>. To identify the efficacy and safety of HIVEC, we conducted this meta-analysis. <i>Methods</i>. We identified relevant articles from PubMed, Embase, and Cochrane Library databases. All published randomized controlled trials (RCTs) describing the role of bladder instillation for the treatment of intermediate- and high-risk NMIBC were involved. Outcomes included 1–3 years Recurrence-Free Survival (RFS), 1–3 years Progression-Free Survival (PFS), 5 years Overall Survival (OS), Adverse Events (AEs), and relevant subgroup analyses. <i>Result</i>. Our study involved a total of 10 RCTs and 1360 patients. In subgroup analysis, we found that compared to MMC instillation, HIVEC decreased the 1–3 years RFS (OR = 0.51; <i>p</i> = 0.009) while not increasing the incidence of AEs (OR = 0.86; <i>p</i> = 0.30). Compared with BCG instillation, HIVEC reduced the incidence of serious AEs (OR = 0.21; <i>p</i> = 0.04) while bringing the same efficacy (OR = 0.78; <i>p</i> = 0.63). <i>Conclusion</i>. HIVEC combined the advantages of efficacy and safety compared with the two recommended instillation modalities. As a potential alternative therapy, its widespread clinical effect remains to be further evaluated.</p>\",\"PeriodicalId\":13782,\"journal\":{\"name\":\"International Journal of Clinical Practice\",\"volume\":\"2024 1\",\"pages\":\"\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2024-05-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Clinical Practice\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1155/2024/9916707\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Clinical Practice","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1155/2024/9916707","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

摘要

背景。为了预防经尿道膀胱肿瘤切除术(TURBT)后中高危非肌浸润性膀胱癌(NMIBC)的复发和进展,近年来已开发出多种膀胱灌注疗法。其中,设备辅助热疗膀胱内化疗(Hyperthermic Intravesical Chemotherapy,HIVEC)受到了广泛关注。目的为了确定 HIVEC 的有效性和安全性,我们进行了这项荟萃分析。方法我们从 PubMed、Embase 和 Cochrane Library 数据库中查找了相关文章。所有已发表的描述膀胱灌注治疗中高危 NMIBC 作用的随机对照试验(RCT)均被纳入其中。结果包括 1-3 年无复发生存期(RFS)、1-3 年无进展生存期(PFS)、5 年总生存期(OS)、不良事件(AEs)以及相关亚组分析。研究结果我们的研究共涉及 10 项 RCT 和 1360 名患者。在亚组分析中,我们发现与 MMC 灌注相比,HIVEC 降低了 1-3 年的 RFS(OR = 0.51;),同时没有增加 AE 的发生率(OR = 0.86;)。与卡介苗灌注相比,HIVEC 降低了严重 AEs 的发生率(OR = 0.21;),同时带来了相同的疗效(OR = 0.78;)。结论与推荐的两种灌注方式相比,HIVEC兼具疗效和安全性的优点。作为一种潜在的替代疗法,其广泛的临床效果仍有待进一步评估。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
The Efficacy and Safety of Hyperthermic Intravesical Chemotherapy Compared with Other Instillation Methods in Treating Intermediate- and High-Risk Non-Muscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis

Background. In order to prevent the recurrence and progression of intermediate- and high-risk non-muscle invasive bladder cancer (NMIBC) after transurethral resection of bladder tumor (TURBT), various bladder instillation therapies have been developed in recent years. Among these, device-assisted Hyperthermic Intravesical Chemotherapy (HIVEC) has received a great deal of attention. Objective. To identify the efficacy and safety of HIVEC, we conducted this meta-analysis. Methods. We identified relevant articles from PubMed, Embase, and Cochrane Library databases. All published randomized controlled trials (RCTs) describing the role of bladder instillation for the treatment of intermediate- and high-risk NMIBC were involved. Outcomes included 1–3 years Recurrence-Free Survival (RFS), 1–3 years Progression-Free Survival (PFS), 5 years Overall Survival (OS), Adverse Events (AEs), and relevant subgroup analyses. Result. Our study involved a total of 10 RCTs and 1360 patients. In subgroup analysis, we found that compared to MMC instillation, HIVEC decreased the 1–3 years RFS (OR = 0.51; p = 0.009) while not increasing the incidence of AEs (OR = 0.86; p = 0.30). Compared with BCG instillation, HIVEC reduced the incidence of serious AEs (OR = 0.21; p = 0.04) while bringing the same efficacy (OR = 0.78; p = 0.63). Conclusion. HIVEC combined the advantages of efficacy and safety compared with the two recommended instillation modalities. As a potential alternative therapy, its widespread clinical effect remains to be further evaluated.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
5.30
自引率
0.00%
发文量
274
审稿时长
3-8 weeks
期刊介绍: IJCP is a general medical journal. IJCP gives special priority to work that has international appeal. IJCP publishes: Editorials. IJCP Editorials are commissioned. [Peer reviewed at the editor''s discretion] Perspectives. Most IJCP Perspectives are commissioned. Example. [Peer reviewed at the editor''s discretion] Study design and interpretation. Example. [Always peer reviewed] Original data from clinical investigations. In particular: Primary research papers from RCTs, observational studies, epidemiological studies; pre-specified sub-analyses; pooled analyses. [Always peer reviewed] Meta-analyses. [Always peer reviewed] Systematic reviews. From October 2009, special priority will be given to systematic reviews. [Always peer reviewed] Non-systematic/narrative reviews. From October 2009, reviews that are not systematic will be considered only if they include a discrete Methods section that must explicitly describe the authors'' approach. Special priority will, however, be given to systematic reviews. [Always peer reviewed] ''How to…'' papers. Example. [Always peer reviewed] Consensus statements. [Always peer reviewed] Short reports. [Always peer reviewed] Letters. [Peer reviewed at the editor''s discretion] International scope IJCP publishes work from investigators globally. Around 30% of IJCP articles list an author from the UK. Around 30% of IJCP articles list an author from the USA or Canada. Around 45% of IJCP articles list an author from a European country that is not the UK. Around 15% of articles published in IJCP list an author from a country in the Asia-Pacific region.
期刊最新文献
High Prevalence of Unrecorded Stage 3 Chronic Kidney Disease in Australia, Brazil, Canada, England, and Spain: The Multinational, Observational REVEAL-CKD Study Influencing Factors for Depression and Depression Aggravation in Hospitalized Elderly Patients With Chronic Heart Failure Blood Urea Nitrogen to Albumin Ratio Was Associated With Mortality in Critically Ill Septic Patients: A Multicenter Retrospective Propensity–Adjusted Analysis Affordability of Original and Generic Antihypertensive Drugs Under the National Centralized Drug Procurement Policy and Basic Medical Insurance System: A Cross-Sectional Survey in Xi’an, China Guidelines for Returning to Dance Following Concussion: Adaptations From Sport Concussion Literature
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1